Younger patients often require repeat corneal crosslinking, study finds

The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California

The researchers shared the first cohort study established in China that examines the relationship between secondhand smoke and early onset of myopia

Remaining questions about DED pertain to geographic considerations, prevalence measures for DED in children and the design of future studies to determine risk factors in patients under 40

The global prevalence of myopia has surged, and is expected to affect nearly 5 billion people by 2050

Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture

Cabozantinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has previously been associated with hepatic and dermatologic adverse effects